Growth Hormone and Bone*
The DOI matches its Crossref record; 274 of the 274 references it cites were found in a registry or an index.
Abstract
It is well known that GH is important in the regulation of longitudinal bone growth. Its role in the regulation of bone metabolism in man has not been understood until recently. Several in vivo and in vitro studies have demonstrated that GH is important in the regulation of both bone formation and bone resorption. In Figure 9 a simplified model for the cellular effects of GH in the regulation of bone remodeling is presented (Fig. 9). GH increases bone formation in two ways: via a direct interaction with GHRs on osteoblasts and via an induction of endocrine and autocrine/paracrine IGF-I. It is difficult to say how much of the GH effect is mediated by IGFs and how much is IGF-independent. GH treatment also results in increased bone resorption. It is still unknown whether osteoclasts express functional GHRs, but recent in vitro studies indicate that GH regulates osteoclast formation in bone marrow cultures. Possible modulations of the GH/IGF axis by glucocorticoids and estrogens are also included in Fig. 9. GH deficiency results in a decreased bone mass in both man and experimental animals. Long-term treatment (> 18 months) of GHD patients with GH results in an increased bone mass. GH treatment also increases bone mass and the total mechanical strength of bones in rats with a normal GH secretion. Recent clinical studies demonstrate that GH treatment of patients with normal GH secretion increases biochemical markers for both bone formation and bone resorption. Because of the short duration of GH treatment in man with normal GH secretion, the effect on bone mass is still inconclusive. Interestingly, GH treatment to GHD adults initially results in increased bone resorption with an increased number of bone-remodeling units and more newly produced unmineralized bone, resulting in an apparent low or unchanged bone mass. However, GH treatment for more than 18 months gives increased bone formation and bone mineralization of newly produced bone and a concomitant increase in bone mass as determined with DEXA. Thus, the action of GH on bone metabolism in GHD adults is 2-fold: it stimulates both bone resorption and bone formation. We therefore propose "the biphasic model" of GH action in bone remodeling (Fig. 10). According to this model, GH initially increases bone resorption with a concomitant bone loss that is followed by a phase of increased bone formation. After the moment when bone formation is stimulated more than bone resorption (transition point), bone mass is increased. However, a net gain of bone mass caused by GH may take some time as the initial decrease in bone mass must first be replaced (Fig. 10). When all clinical studies of GH treatment of GHD adults are taken into account, it appears that the "transition point" occurs after approximately 6 months and that a net increase of bone mass will be seen after 12-18 months of GH treatment. It should be emphasized that the biphasic model of GH action in bone remodeling is based on findings in GHD adults. It remains to be clarified whether or not it is valid for subjects with normal GH secretion. A treatment intended to increase the effects of GH/IGF-I axis on bone metabolism might include: 1) GH, 2) IGF, 3) other hormones/factors increasing the local IGF-I production in bone, and 4) GH-releasing factors. Other hormones/growth factors increasing local IGF may be important but are not discussed in this article. IGF-I has been shown to increase bone mass in animal models and biochemical markers in humans. However, no effect on bone mass has yet been presented in humans. Because the financial cost for GH treatment is high it has been suggested that GH-releasing factors might be used to stimulate the GH/IGF-I axis. The advantage of GH-releasing factors over GH is that some of them can be administered orally and that they may induce a more physiological GH secretion. (ABSTRACT TRUNCATED)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liu, J.-P., Baker, J., Perkins, A. S., Robertson, E. J., & Efstratiadis, A. (1993) · Cell · doi:10.1016/s0092-8674(05)80084-4 · Cited by 2,855
Role of insulin-like growth factors in embryonic and postnatal growth
Baker, J., Liu, J.-P., Robertson, E. J., & Efstratiadis, A. (1993) · Cell · doi:10.1016/s0092-8674(05)80085-6 · Cited by 2,463
DAUGHADAY, W. H., & ROTWEIN, P. (1989) · Endocrine Reviews · doi:10.1210/edrv-10-1-68 · Cited by 1,725
Basic biomechanical measurements of bone: A tutorial
Turner, C. H., & Burr, D. B. (1993) · Bone · doi:10.1016/8756-3282(93)90081-k · Cited by 1,666
Effects of Human Growth Hormone in Men over 60 Years Old
Rudman, D., Feller, A. G., Nagraj, H. S., Gergans, G. A., Lalitha, P. Y., Goldberg, A. F., Schlenker, R. A., Cohn, L., Rudman, I. W., & Mattson, D. E. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007053230101 · Cited by 1,555
The ovariectomized rat model of postmenopausal bone loss
Kalu, D. N. (1991) · Bone and Mineral · doi:10.1016/0169-6009(91)90124-i · Cited by 1,361
Palmiter, R. D., Brinster, R. L., Hammer, R. E., Trumbauer, M. E., Rosenfeld, M. G., Birnberg, N. C., & Evans, R. M. (1982) · Nature · doi:10.1038/300611a0 · Cited by 1,340
D'Ercole, A. J., Stiles, A. D., & Underwood, L. E. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.3.935 · Cited by 1,186
Growth Hormone and the Insulin-Like Growth Factor System in Myogenesis*
FLORINI, J. R., EWTON, D. Z., & COOLICAN, S. A. (1996) · Endocrine Reviews · doi:10.1210/edrv-17-5-481 · Cited by 1,142
Raynal, P., & Pollard, H. B. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/0304-4157(94)90019-1 · Cited by 1,099
Cited by
Bone's mechanostat: A 2003 update
Frost, H. M. (2003) · The Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology · doi:10.1002/ar.a.10119 · Cited by 1,535
The Somatomedin Hypothesis: 2001
Le Roith, D., Bondy, C., Yakar, S., Liu, J.-L., & Butler, A. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.1.0419 · Cited by 1,257
Bose, S., & Tarafder, S. (2012) · Acta Biomaterialia · doi:10.1016/j.actbio.2011.11.017 · Cited by 958
The Role of Zinc in Growth and Cell Proliferation
MacDonald, R. S. (2000) · The Journal of Nutrition · doi:10.1093/jn/130.5.1500s · Cited by 954
Sjögren, K., Liu, J.-L., Blad, K., Skrtic, S., Vidal, O., Wallenius, V., LeRoith, D., Törnell, J., Isaksson, O. G. P., Jansson, J.-O., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.7088 · Cited by 938
Self-citationDiscovery of Human Zinc Deficiency: Its Impact on Human Health and Disease
Prasad, A. S. (2013) · Advances in Nutrition · doi:10.3945/an.112.003210 · Cited by 919
“Zinc deficiency decreases circulating insulin-like growth factor 1 (IGF-1) concentration independent of total energy intake (29) .”
BackgroundGrowth Hormone, Insulin-Like Growth Factors, and the Skeleton
Giustina, A., Mazziotti, G., & Canalis, E. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0036 · Cited by 914
Roles of Growth Hormone and Insulin-like Growth Factor 1 in Mouse Postnatal Growth
Lupu, F., Terwilliger, J. D., Lee, K., Segre, G. V., & Efstratiadis, A. (2001) · Developmental Biology · doi:10.1006/dbio.2000.9975 · Cited by 771
Vanderschueren, D., Vandenput, L., Boonen, S., Lindberg, M. K., Bouillon, R., & Ohlsson, C. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0003 · Cited by 717
Self-citationDe Souza, M. J., Nattiv, A., Joy, E., Misra, M., Williams, N. I., Mallinson, R. J., Gibbs, J. C., Olmsted, M., Goolsby, M., Matheson, G., et al. (2014) · British Journal of Sports Medicine · doi:10.1136/bjsports-2013-093218 · Cited by 661
Insulin-like growth factor 1 (IGF-1): a growth hormone
Laron, Z. (2001) · Molecular Pathology · doi:10.1136/mp.54.5.311 · Cited by 608
Distinct and Overlapping Functions of Insulin and IGF-I Receptors
Nakae, J., Kido, Y., & Accili, D. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.6.0452 · Cited by 554
Riggs, B. L., Melton, L. J., Robb, R. A., Camp, J. J., Atkinson, E. J., McDaniel, L., Amin, S., Rouleau, P. A., & Khosla, S. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.071020 · Cited by 542
Sandhu, M. S. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.13.972 · Cited by 496
The Role of Liver-Derived Insulin-Like Growth Factor-I
Ohlsson, C., Mohan, S., Sjögren, K., Tivesten, A., Isgaard, J., Isaksson, O., Jansson, J.-O., & Svensson, J. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0010 · Cited by 453
Self-citationEndocrine Control of Body Composition in Infancy, Childhood, and Puberty
Veldhuis, J. D., Roemmich, J. N., Richmond, E. J., Rogol, A. D., Lovejoy, J. C., Sheffield-Moore, M., Mauras, N., & Bowers, C. Y. (2005) · Endocrine Reviews · doi:10.1210/er.2003-0038 · Cited by 452
Gothe, S., Wang, Z., Ng, L., Kindblom, J. M., Barros, A. C., Ohlsson, C., Vennstrom, B., & Forrest, D. (1999) · Genes & Development · doi:10.1101/gad.13.10.1329 · Cited by 445
Self-citationMårtensson, U. E. A., Salehi, S. A., Windahl, S., Gomez, M. F., Swärd, K., Daszkiewicz-Nilsson, J., Wendt, A., Andersson, N., Hellstrand, P., Grände, P.-O., et al. (2009) · Endocrinology · doi:10.1210/en.2008-0623 · Cited by 413
Self-citationEstrogen receptor specificity in the regulation of skeletal growth and maturation in male mice
Vidal, O., Lindberg, M. K., Hollberg, K., Baylink, D. J., Andersson, G., Lubahn, D. B., Mohan, S., Gustafsson, J.-Å., & Ohlsson, C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.10.5474 · Cited by 386
Self-citationButler, A. A., & Roith, D. L. (2001) · Annual Review of Physiology · doi:10.1146/annurev.physiol.63.1.141 · Cited by 385
Borer, K. T. (2005) · Sports Medicine · doi:10.2165/00007256-200535090-00004 · Cited by 373
Osteoporosis Due to Cancer Treatment: Pathogenesis and Management
Pfeilschifter, J., & Diel, I. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1570 · Cited by 363
van der Sluis, I. M. (2002) · Archives of Disease in Childhood · doi:10.1136/adc.87.4.341 · Cited by 362
Bredella, M. A., Torriani, M., Ghomi, R. H., Thomas, B. J., Brick, D. J., Gerweck, A. V., Rosen, C. J., Klibanski, A., & Miller, K. K. (2011) · Obesity · doi:10.1038/oby.2010.106 · Cited by 348
Ghrelin Directly Regulates Bone Formation
Fukushima, N., Hanada, R., Teranishi, H., Fukue, Y., Tachibana, T., Ishikawa, H., Takeda, S., Takeuchi, Y., Fukumoto, S., Kangawa, K., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041237 · Cited by 319
The endocrine manifestations of anorexia nervosa: mechanisms and management
Schorr, M., & Miller, K. K. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.175 · Cited by 316
Misra, M., Miller, K. K., Almazan, C., Ramaswamy, K., Lapcharoensap, W., Worley, M., Neubauer, G., Herzog, D. B., & Klibanski, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0723 · Cited by 316
Effect of GH/IGF-1 on Bone Metabolism and Osteoporsosis
Locatelli, V., & Bianchi, V. E. (2014) · International Journal of Endocrinology · doi:10.1155/2014/235060 · Cited by 307
Dehkhoda, F., Lee, C. M. M., Medina, J., & Brooks, A. J. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00035 · Cited by 304
“In terms of efficacy, GH and IGF-1 both stimulated linear growth but some variables including the greater growth deficit in infants with Laron syndrome than those with isolated growth hormone deficiency, insufficient IGF-1 dose, or the IGF-1 dependency on the GH-linked stem cell population of prechondrocytes made GH m…”
BackgroundTelling facial metrics: facial width is associated with testosterone levels in men
Lefevre, C. E., Lewis, G. J., Perrett, D. I., & Penke, L. (2013) · Evolution and Human Behavior · doi:10.1016/j.evolhumbehav.2013.03.005 · Cited by 293
The role of leptin in regulating bone metabolism
Upadhyay, J., Farr, O. M., & Mantzoros, C. S. (2015) · Metabolism · doi:10.1016/j.metabol.2014.10.021 · Cited by 268
Wüster, C., Abs, R., Bengtsson, B.-Å., Bennmarker, H., Feldt-Rasmussen, U., Hernberg-Ståhl, E., Monson, J. P., Westberg, B., & Wilton, P. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.398 · Cited by 267
Self-citationAkt1 in Osteoblasts and Osteoclasts Controls Bone Remodeling
Kawamura, N., Kugimiya, F., Oshima, Y., Ohba, S., Ikeda, T., Saito, T., Shinoda, Y., Kawasaki, Y., Ogata, N., Hoshi, K., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001058 · Cited by 258
Corbacho, A., Martinez De La Escalera, G., & Clapp, C. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1730219 · Cited by 256
Igf1 promotes longitudinal bone growth by insulin‐like actions augmenting chondrocyte hypertrophy
Wang, J., Zhou, J., & Bondy, C. A. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.14.1985 · Cited by 253
Interactions between GH, IGF-I, Glucocorticoids, and Thyroid Hormones during Skeletal Growth
Robson, H., Siebler, T., Shalet, S. M., & Williams, G. R. (2002) · Pediatric Research · doi:10.1203/00006450-200208000-00003 · Cited by 215
“IGF-I is proposed then to stimulate clonal expansion of proliferating cells in an autocrine/paracrine manner (48).”
BackgroundHoffman, A. R., Kuntze, J. E., Baptista, J., Baum, H. B. A., Baumann, G. P., Biller, B. M. K., Clark, R. V., Cook, D., Inzucchi, S. E., Kleinberg, D., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030346 · Cited by 185
Mazziotti, G., Frara, S., & Giustina, A. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00005 · Cited by 181
Greenhalgh, C. J., Bertolino, P., Asa, S. L., Metcalf, D., Corbin, J. E., Adams, T. E., Davey, H. W., Nicola, N. A., Hilton, D. J., & Alexander, W. S. (2002) · Molecular Endocrinology · doi:10.1210/me.16.6.1394 · Cited by 166
Mazziotti, G., Bianchi, A., Bonadonna, S., Nuzzo, M., Cimino, V., Fusco, A., De Marinis, L., & Giustina, A. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060112 · Cited by 141
“GROWTH HORMONE (GH) plays a key role in the control of longitudinal growth and has important stimulatory effects on bone remodeling and bone mass.((1)) The progressive decline of GH secretion((2)) is considered to be among the factors contributing to age-related and postmenopausal bone loss.”
BackgroundHormone Replacement Therapy and Physical Function in Healthy Older Men. Time to Talk Hormones?
Giannoulis, M. G., Martin, F. C., Nair, K. S., Umpleby, A. M., & Sonksen, P. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1002 · Cited by 132
Bariatric surgery, bone loss, obesity and possible mechanisms
Brzozowska, M. M., Sainsbury, A., Eisman, J. A., Baldock, P. A., & Center, J. R. (2013) · Obesity Reviews · doi:10.1111/j.1467-789x.2012.01050.x · Cited by 128
O’Shea, P. J., Bassett, J. H. D., Sriskantharajah, S., Ying, H., Cheng, S.-Y., & Williams, G. R. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0224 · Cited by 126
Claessen, K. M. J. A., Kroon, H. M., Pereira, A. M., Appelman-Dijkstra, N. M., Verstegen, M. J., Kloppenburg, M., Hamdy, N. A. T., & Biermasz, N. R. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2695 · Cited by 111
“The high VF prevalence observed in acromegalic patients was interestingly associated with a normal BMD (13), suggesting that BMD is a poor predictor of fracture risk in acromegaly, as is also the case in other forms of secondary osteoporosis (3, 4, 31).”
The cartilage extracellular matrix as a transient developmental scaffold for growth plate maturation
Melrose, J., Shu, C., Whitelock, J. M., & Lord, M. S. (2016) · Matrix Biology · doi:10.1016/j.matbio.2016.01.008 · Cited by 96
Bielohuby, M., Matsuura, M., Herbach, N., Kienzle, E., Slawik, M., Hoeflich, A., & Bidlingmaier, M. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090813 · Cited by 85
“The GH/IGF system represents another crucial hormonal system to control bone growth.((20)) Analysis of body composition and bone mineral”
BackgroundIncidence of morphometric vertebral fractures in adult patients with growth hormone deficiency
Mazziotti, G., Doga, M., Frara, S., Maffezzoni, F., Porcelli, T., Cerri, L., Maroldi, R., & Giustina, A. (2016) · Endocrine · doi:10.1007/s12020-015-0738-z · Cited by 78
Drake, W. M., Rodríguez‐Arnao, J., Weaver, J. U., James, I. T., Coyte, D., Spector, T. D., Besser, G. M., & Monson, J. P. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01246.x · Cited by 76
Bolanowski, M., Daroszewski, J., Mędraś, M., & Zadrożna-Śliwka, B. (2005) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-005-0649-9 · Cited by 74
“Acromegaly is not associated with increased risk of fractures [10].”
BackgroundFracture Incidence in GH-Deficient Patients on Complete Hormone Replacement Including GH
Holmer, H., Svensson, J., Rylander, L., Johannsson, G., Rosén, T., Bengtsson, B.-Å., Thorén, M., Höybye, C., Degerblad, M., Bramnert, M., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070811 · Cited by 66
“GROWTH HORMONE (GH) affects linear growth and is important for skeletal development in young adults and for bone turnover in adult skeletal tissue.((1)) Reduced BMD has been recorded both in patients with isolated GH deficiency (GHD) and in those with multiple pituitary deficiencies, indicating that GHD per se is resp…”
BackgroundMethodSelf-citationNovel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis
Filip, R., Radzki, R., & Bieńko, M. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s170533 · Cited by 60
“human GH accelerated the rate of bone turnover improving bone metabolism in postmenopausal women.(47)”
BackgroundInsulin-like growth factors and skeletal growth: possibilities for therapeutic interventions
Van Wyk, J. J., & Smith, E. P. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.12.6201 · Cited by 53
“Ohlsson has postulated that GH is required for providing an adequate stem cell population of prechondrocytes (24).”
BackgroundMazziotti, G., Chiavistelli, S., & Giustina, A. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.10.014 · Cited by 46
Bone circuitry and interorgan skeletal crosstalk
Zaidi, M., Kim, S.-M., Mathew, M., Korkmaz, F., Sultana, F., Miyashita, S., Gumerova, A. A., Frolinger, T., Moldavski, O., Barak, O., et al. (2023) · eLife · doi:10.7554/elife.83142 · Cited by 45
“enhanced cartilage growth in hypophysectomized and GHdeficient rodents (Isaksson et al., 1987; Isaksson et al., 1991; Ohlsson et al., 1998) and reversed the osteopenic phenotype of estrogen-”
BackgroundImpact of the growth hormone replacement on bone status in growth hormone deficient adults
Kužma, M., Kužmová, Z., Zelinková, Z., Killinger, Z., Vaňuga, P., Lazurová, I., Tomková, S., & Payer, J. (2014) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2013.12.001 · Cited by 43
Effects of 6 years of growth hormone (GH) treatment on bone mineral density in GH‐deficient adults
Clanget, C., Seck, T., Hinke, V., Wüster, C., Ziegler, R., & Pfeilschifter, J. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01284.x · Cited by 42
Lv, Q.-B., Fu, X., Jin, H.-M., Xu, H.-C., Huang, Z.-Y., Xu, H.-Z., Chi, Y.-L., & Wu, A.-M. (2015) · Scientific Reports · doi:10.1038/srep16030 · Cited by 38
Estrogen Deficiency, Postmenopausal Osteoporosis, and Age-Related Bone Loss
Khosla, S., & Pacifici, R. (2013) · Osteoporosis · doi:10.1016/b978-0-12-415853-5.00046-7 · Cited by 31
Rota, F., Savanelli, M. C., Tauchmanova, L., Savastano, S., Lombardi, G., Colao, A., & Di Somma, C. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03345574 · Cited by 25
Quantitative Ultrasound of the Heel and Some Parameters of Bone Turnover in Patients with Acromegaly
Bolanowski, M., Jędrzejuk, D., Milewicz, A., & Arkowska, A. (2002) · Osteoporosis International · doi:10.1007/s001980200030 · Cited by 21
“It stimulates bone formation directly and at least partly by locally produced IGF-1 [16].”
BackgroundRagnar Agnarsson, H., Johannsson, G., & Ragnarsson, O. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3851 · Cited by 10
Metadata
- Authors
- Ohlsson, C., Bengtsson, B.-A., Isaksson, O. G. P., Andreassen, T. T., & Slootweg, M. C.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 1998-02-01
- Volume
- 19
- Issue
- 1
- Pages
- 55-79
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2172818901
- Cited by
- 855
- References
- 274
- FWCI
- 26.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.